Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Why Telix (ASX:TLX) Fell 20% After FDA News – And What Investors Should Know

When expectations fall short, sentiment can shift in an instant. That is exactly what happened with Telix Pharmaceuticals (ASX: TLX) after the company received an unexpected setback from the U.S. Food and Drug Administration. TLX had applied for approval of TLX250-CDx, an innovative imaging agent designed to help doctors more accurately diagnose kidney…

ByCharlie YouldenAugust 28, 2025

Galidesivir has made Island Pharmaceuticals the ultimate ‘America First’ play for ASX investors!

Think of 'America First' ASX stocks and Island Pharmaceuticals (ASX:ILA) typically hasn't come to mind, but its acquisition of Galidesivir should put it firmly in the list. You cannot question the data that the company is in possession of, but some investors may think a company with plans to undertake an 'animal study' is years…

ByNick SundichAugust 27, 2025

Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?

Nova Eye Medical (ASX:EYE) is no clinical stage medtech company, but has just an exciting 12 months ahead as if it was a clinical stage company with company-making catalysts ahead. Because even though it has commercialised its devices, a major 12 months are ahead during which it is expected to make major inroads in the US…

ByNick SundichAugust 27, 2025

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Here are 5 ASX biotechs expecting clinical trial results in the next few months! Dimerix (ASX:DXB) Dimerix is in the middle of a Phase III trial or its DMX-200 drug for a condition known as Focal Segmental Glomerulosclerosis (FSGS). For patients with FSGS, the kidneys’ ability to purify (clean) the blood is impaired. This can…

ByNick SundichAugust 27, 2025

Why Investors Are Watching Nanosonics (ASX: NAN) After a Strong Earnings Surge

Is CORIS the Catalyst for Nanosonics’ (ASX: NAN) Next Phase of Expansion? Nanosonics (ASX: NAN) has caught the market’s attention, with its share price climbing 14 percent over the past week as excitement built ahead of its full-year results. The earnings release did not disappoint, giving investors fresh confidence in the company’s long-term growth story. At…

ByCharlie YouldenAugust 26, 2025

4 reasons why Pro Medicus (ASX:PME) just keeps rising to new heights

Another reporting season, another impressive result from Pro Medicus (ASX:PME). Eerily similar to the debate going on about CBA (ASX:CBA), investors debate about whether or not it is overvalued or undervalued, but the share price just keeps going up. We are not going to state our view on where it is headed next, although we…

ByNick SundichAugust 25, 2025

Is the Market Missing Telix’s Long-Term Potential after 63% Revenue Growth?

Telix Pharmaceuticals: Controversy, Growth, and the Road Ahead Every investor knows the uneasy feeling of watching a stock fall, not because of poor earnings, but because of controversy. That is the position Telix Pharmaceuticals (ASX: TLX) finds itself in today. After headlines about an FDA subpoena related to how it communicated drug progress to investors,…

ByCharlie YouldenAugust 21, 2025

Argent BioPharma Jumps 86% After Bold AusCann Acquisition

Argent BioPharma Expands with AusCann Deal On August 19, Argent BioPharma (ASX: RGT) announced it was buying AusCann’s assets, which include the 100% ownership of the Neuvis drug delivery platform, 48% of CannPal Animal Therapeutics, and part of 20% of ECC Pharm. This deal gives Argent new technology, more research data, and access to the…

ByCharlie YouldenAugust 19, 2025

CSL FY25 Analysis 14% Profit Growth Despite Slower Revenue Growth

CSL’s Growth Slows, Profits Surge: What Investors Need to Know For decades, CSL Limited (ASX: CSL) has been regarded as one of Australia’s most dependable healthcare giants, the kind of stock you could tuck away and forget. Yet in recent years, even this blue-chip defensive stock has shown it is not immune to market turbulence.…

ByCharlie YouldenAugust 19, 2025

ASX Health Care Stocks Under Trump: Who’ll Win and Who’ll Lose?

What does the next few years hold for ASX Health Care Stocks Under Trump? There's no doubt that the health care sector is bearing a greater brunt than any other ASX sector. Investors are concerned about tariffs on Australian imports, and the potential for the Pharmaceutical Benefits Scheme to be disrupted. The latter makes medicines available…

ByNick SundichAugust 18, 2025